IKT Inhibikase Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IKT

Price (delayed)

$2.15

Market cap

$300M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$268.8M

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 80
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5
Highlights
The company's debt has shrunk by 100% YoY
The equity has soared by 92% year-on-year but it has declined by 9% since the previous quarter
IKT's quick ratio has surged by 56% year-on-year but it is down by 48% since the previous quarter
Inhibikase Therapeutics's net income has decreased by 46% YoY and by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inhibikase.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IKT

IKT stock price

How has the Inhibikase Therapeutics stock price performed over time
Intraday
-6.93%
1 week
-6.93%
1 month
-10.04%
1 year
32.72%
YTD
4.88%
QTD
5.91%

Financial performance

How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.66M
Net income
-$60.64M
Gross margin
N/A
Net margin
N/A
Inhibikase Therapeutics's net income has decreased by 46% YoY and by 19% from the previous quarter
Inhibikase Therapeutics's operating income has decreased by 44% YoY and by 18% from the previous quarter

Price vs fundamentals

How does IKT's price correlate with its fundamentals

Growth

What is Inhibikase Therapeutics's growth rate over time

Valuation

What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
1.85
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The equity has soared by 92% year-on-year but it has declined by 9% since the previous quarter
The stock's price to book (P/B) is 66% more than its 5-year quarterly average of 1.2 and 42% more than its last 4 quarters average of 1.4

Efficiency

How efficient is Inhibikase Therapeutics business performance
IKT's return on invested capital has surged by 75% year-on-year and by 27% since the previous quarter
IKT's return on equity is up by 33% year-on-year but it is down by 3.6% since the previous quarter
The return on assets is up by 30% year-on-year but it has declined by 4.1% since the previous quarter

Dividends

What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IKT.

Financial health

How did Inhibikase Therapeutics financials performed over time
The total assets has surged by 84% year-on-year but it has declined by 6% since the previous quarter
IKT's total liabilities has surged by 80% since the previous quarter and by 17% year-on-year
The company's debt is 100% lower than its equity
The company's debt has shrunk by 100% YoY
The equity has soared by 92% year-on-year but it has declined by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.